224 related articles for article (PubMed ID: 24615009)
21. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia.
Xu W; Wang YH; Fan L; Fang C; Zhu DX; Wang DM; Qiao C; Wu YJ; Li JY
Leuk Res; 2011 Aug; 35(8):1060-5. PubMed ID: 21208658
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
24. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
26. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
Haferlach C; Dicker F; Weiss T; Schnittger S; Beck C; Grote-Metke A; Oruzio D; Kern W; Haferlach T
Genes Chromosomes Cancer; 2010 Sep; 49(9):851-9. PubMed ID: 20552631
[TBL] [Abstract][Full Text] [Related]
27. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
[TBL] [Abstract][Full Text] [Related]
28. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
29. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
30. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
[TBL] [Abstract][Full Text] [Related]
31. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
32. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.
Lin K; Sherrington PD; Dennis M; Matrai Z; Cawley JC; Pettitt AR
Blood; 2002 Aug; 100(4):1404-9. PubMed ID: 12149224
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
34. Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients.
Briani C; Visentin A; Salvalaggio A; Imbergamo S; Piazza F; Cacciavillani M; Campagnolo M; Frezzato F; Semenzato G; Trentin L
Haematologica; 2017 Apr; 102(4):e140-e143. PubMed ID: 27927770
[No Abstract] [Full Text] [Related]
35. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.
Sturm I; Bosanquet AG; Hummel M; Dörken B; Daniel PT
BMC Cancer; 2005 Aug; 5():105. PubMed ID: 16109171
[TBL] [Abstract][Full Text] [Related]
36. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
[TBL] [Abstract][Full Text] [Related]
37. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
38. Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.
Zakrzewska E; Pirog M; Purkot J; Giannopoulos K
Folia Histochem Cytobiol; 2017; 55(3):95-106. PubMed ID: 28994094
[TBL] [Abstract][Full Text] [Related]
39. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Rassenti LZ; Jain S; Keating MJ; Wierda WG; Grever MR; Byrd JC; Kay NE; Brown JR; Gribben JG; Neuberg DS; He F; Greaves AW; Rai KR; Kipps TJ
Blood; 2008 Sep; 112(5):1923-30. PubMed ID: 18577710
[TBL] [Abstract][Full Text] [Related]
40. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.
Rossi D; Rasi S; Fabbri G; Spina V; Fangazio M; Forconi F; Marasca R; Laurenti L; Bruscaggin A; Cerri M; Monti S; Cresta S; Famà R; De Paoli L; Bulian P; Gattei V; Guarini A; Deaglio S; Capello D; Rabadan R; Pasqualucci L; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Jan; 119(2):521-9. PubMed ID: 22077063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
